Clinical Trial

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

Recruiting
View on ClinicalTrials.gov →
Summary
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-28.
Trial Details
NCT Number NCT07276425
Lead Sponsor UMC Utrecht
Collaborators: Sanofi
Conditions Prurigo Nodularis (PN)
Enrollment 40 participants
Start Date 2025-06-01
Primary Completion 2028-06-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-18